Targeting central nervous system pathologies with nanomedicines

References

• Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7:41–53. .
   PubMed Web of Science ®Google Scholar
• Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol. 2002;38:323–337.
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anatomy. 2002;200:629–638. Jun PubMed PMID: 12162730; PubMed Central PMCID: PMC1570746.
   PubMed Web of Science ®Google Scholar
• Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57:173–185.
   PubMed Web of Science ®Google Scholar
• Rosenblum D, Joshi N, Tao W. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9:1410.
   PubMed Web of Science ®Google Scholar
• Chen CT, Duan ZQ, Yuan Y, et al. Peptide-22 and cyclic RGD functionalized liposomes for glioma targeting drug delivery overcoming BBB and BBTB. ACS Appl Mater Interfaces. 2017;9:5864–5873.
   PubMed Web of Science ®Google Scholar
• Summerfield S, Jeffrey P, Sahi J, et al. Passive diffusion permeability of the BBB-examples and SAR. Hoboken, NJ: John Wiley & Sons, Inc; 2015. p. 95–112.
   Google Scholar
• Backes WL. Passive diffusion of drugs across membranes. Amsterdam, Netherlands: Elsevier; 2007. p. 1–5.
   Google Scholar
• De Gregori S, De Gregori M, Ranzani GN, et al. Morphine metabolism, transport and brain disposition. Metab Brain Dis. 2012;27:1.
   PubMed Web of Science ®Google Scholar
• Rochat B, Baumann P, Audus KL. Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Res. 1999;831:229–236.
   PubMed Web of Science ®Google Scholar
• Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. Am J Pharmacol Sci. 2000;89:1371–1388.
   Google Scholar
• Devraj K, Klinger ME, Myers RL, et al. GLUT-1 glucose transporters in the blood-brain barrier: differential phosphorylation. J Neurosci Res. 2011;89:1913–1925.
   PubMed Web of Science ®Google Scholar
• Qin Y, Fan W, Chen H, et al. In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J Drug Target. 2010;18:536–549.
   PubMed Web of Science ®Google Scholar
• Mergenthaler P, Lindauer U, Dienel GA, et al. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci. 2013;36:587–597.
   PubMed Web of Science ®Google Scholar
• Geldenhuys W, Wehrung D, Groshev A, et al. Brain-targeted delivery of doxorubicin using glutathione-coated nanoparticles for brain cancers. Pharm Dev Technol. 2015;20:497–506.
   PubMed Web of Science ®Google Scholar
• Sanchez-Covarrubias L, Slosky LM, Thompson BJ, et al. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des. 2014;20:1422–1449.
   PubMed Web of Science ®Google Scholar
• Pulicherla KK, Verma MK. Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancements. AAPS PharmSciTech. 2015;16:223–233.
   PubMed Web of Science ®Google Scholar
• Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res. 2007;24:1759–1771.
   PubMed Web of Science ®Google Scholar
• Lu W. Adsorptive-mediated brain delivery systems. Curr Pharm Biotechnol. 2012;13:2340–2348.
   PubMed Web of Science ®Google Scholar
• Hervé F, Ghinea N, Scherrmann J-M. CNS delivery via adsorptive transcytosis. AAPS J. 2008;10:455–472.
   PubMed Web of Science ®Google Scholar
• Banks WA. From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016;15:275–292.
   PubMed Web of Science ®Google Scholar
• Descamps L, Dehouck MP, Torpier G, et al. Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells. Am J Physiol. 1996;270:H1149–H1158.:
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharmaceutics. 2005;2:373–383.
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Hekmatara T, Herbert E, et al. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm eV. 2009;71:251–256.
   PubMed Web of Science ®Google Scholar
• Zhang B, Sun X, Mei H, et al. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. Biomaterials. 2013;34:9171–9182.
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Gibbs AR, Hunt CA, et al. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release. 2007;124:163–171.
   PubMed Web of Science ®Google Scholar
• Thorne RG, Pronk GJ, Padmanabhan V, et al. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127:481–496.
   PubMed Web of Science ®Google Scholar
• Ge S, Song L, Pachter JS. Where is the blood-brain barrier … really? J Neurosci Res. 2005;79:421–427.
   PubMed Web of Science ®Google Scholar
• Kim GY, Tyler BM, Tupper MM, et al. Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. J Control Release. 2007;123:172–178.
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine(BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79–88.
   PubMed Web of Science ®Google Scholar
• Recinos VR, Tyler BM, Bekelis K, et al. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Neurosurgery. 2010;66:530–537; discussion 537.
   PubMed Web of Science ®Google Scholar
• Lu C-T, Zhao Y-Z, Wong HL, et al. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomedicine. 2014;9:2241–2257.
   PubMed Web of Science ®Google Scholar
• Sawyer AJ, Saucier-Sawyer JK, Booth CJ, et al. Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Deliv Transl Res. 2011;1:34–42.
   PubMed Web of Science ®Google Scholar
• Henkin RI. Intranasal delivery to the brain. Nat Biotechnol. 2011;29:480–480.
   PubMed Web of Science ®Google Scholar
• van Woensel M, Wauthoz N, Rosière R, et al. Formulations for intranasal delivery of pharmacological agents to combat brain disease: a new opportunity to tackle GBM? Cancers. 2013;5:1020–1048.
   PubMedGoogle Scholar
• Martinez-Fernandez R, Rodriguez-Rojas R, Del Alamo M, et al. Focused ultrasound subthalamotomy in patients with asymmetric Parkinson's disease: a pilot study. Lancet Neurol. 2018;17:54–63.
   PubMed Web of Science ®Google Scholar
• Zhao Y-Z, Lu C-T, Li X-K, et al. Improving the cardio protective effect of aFGF in ischemic myocardium with ultrasound-mediated cavitation of heparin modified microbubbles: preliminary experiment. J Drug Target. 2012;20:623–631.
   PubMed Web of Science ®Google Scholar
• Treat LH, McDannold N, Vykhodtseva N, et al. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer 2007;121:901–907.
   PubMed Web of Science ®Google Scholar
• Kinoshita M, McDannold N, Jolesz FA, et al. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci. 2006;103:11719–11723.
   PubMed Web of Science ®Google Scholar
• Kinoshita M, McDannold N, Jolesz FA, et al. Targeted delivery of antibodies through the blood–brain barrier by MRI-guided focused ultrasound. Biochem Biophys Res Commun 2005;340:1085–1090.
   PubMed Web of Science ®Google Scholar
• Kemper EM, Boogerd W, Thuis I, et al. Modulation of the blood–brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev. 2004;30:415–423.
   PubMed Web of Science ®Google Scholar
• Azad TD, Pan J, Connolly ID, et al. Therapeutic strategies to improve drug delivery across the blood-brain barrier. Neurosurg Focus. 2015;38:E9.
   PubMed Web of Science ®Google Scholar
• Liu L-b, Xue Y-x, Liu Y-h. Bradykinin increases the permeability of the blood-tumor barrier by the caveolae-mediated transcellular pathway. J Neurooncol. 2010;99:187–194.
   PubMed Web of Science ®Google Scholar
• Bartus RT, Elliott PJ, Dean RL, et al. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol. 1996;142:14–28.
   PubMed Web of Science ®Google Scholar
• Geraerts M, Eggermont K, Hernandez-Acosta P, et al. Lentiviral vectors mediate efficient and stable gene transfer in adult neural stem cells In vivo. Hum Gene Ther. 2006;17:635–650.
   PubMed Web of Science ®Google Scholar
• Morgan JR, Tompkins RG, Yarmush ML. Advances in recombinant retroviruses for gene delivery. Adv Drug Deliv Rev. 1993;12:143–158.
   Web of Science ®Google Scholar
• Lentz TB, Gray SJ, Samulski RJ. Viral vectors for gene delivery to the central nervous system. Neurobiol Dis. 2012;48:179–188.
   PubMed Web of Science ®Google Scholar
• Wolfe D, Goins WF, Yamada M, et al. Engineering Herpes simplex virus vectors for CNS applications. Exp Neurol. 1999;159:34–46.
   PubMed Web of Science ®Google Scholar
• Gutkin A, Cohen ZR, Peer D. Harnessing nanomedicine for therapeutic intervention in glioblastoma. Expert Opin Drug Deliv. 2016;13:1573–1582.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech. 2007;2:751–760.
   PubMed Web of Science ®Google Scholar
• Goldsmith M, Abramovitz L, Peer D. Precision nanomedicine in neurodegenerative diseases. ACS Nano. 2014;8:1958–1965.
   PubMed Web of Science ®Google Scholar
• Key J, Palange AL, Gentile F, et al. Soft discoidal polymeric nanoconstructs resist macrophage uptake and enhance vascular targeting in tumors. ACS Nano. 2015;9:11628–11641.
   PubMed Web of Science ®Google Scholar
• Palomba R, Palange AL, Rizzuti IF, et al. Modulating phagocytic cell sequestration by tailoring nanoconstruct softness. ACS Nano. 2018;12:1433–1444.
   PubMed Web of Science ®Google Scholar
• Toy R, Peiris PM, Ghaghada KB, et al. Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine. 2014;9:121–134.
   PubMed Web of Science ®Google Scholar
• Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small. 2010;6:12–21.
   PubMed Web of Science ®Google Scholar
• Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of toll-like receptor 4 in immune activation. Biomaterials. 2010;31:6867–6875.
   PubMed Web of Science ®Google Scholar
• Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces. 2008;66:274–280.
   PubMed Web of Science ®Google Scholar
• Baghirov H, Karaman D, Viitala T, et al. Feasibility study of the permeability and uptake of mesoporous silica nanoparticles across the blood-brain barrier. PLoS One. 2016;11:e0160705.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Molecular Interventions. 2003 ;3:90–105.
   PubMedGoogle Scholar
• Oller-Salvia B, Sanchez-Navarro M, Giralt E, et al. Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery. Chem Soc Rev. 2016;45:4690–4707.
   PubMed Web of Science ®Google Scholar
• Johnsen KB, Burkhart A, Melander F, et al. Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma. Sci Rep. 2017;47:10396.
   PubMed Web of Science ®Google Scholar
• Jefferies WA, Brandon MR, Hunt SV, et al. Transferrin receptor on endothelium of brain capillaries. Nature 1984;312:162–163.
   PubMed Web of Science ®Google Scholar
• Johnsen KB, Moos T. Revisiting nanoparticle technology for blood-brain barrier transport: unfolding at the endothelial gate improves the fate of transferrin receptor-targeted liposomes. J Control Release. 2016;222:32–46.
   PubMed Web of Science ®Google Scholar
• Yu YJ, Zhang Y, Kenrick M, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3:84ra44.
   PubMed Web of Science ®Google Scholar
• Aktaş Y, Yemisci M, Andrieux K, et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjugate Chem. 2005;16:1503–1511.
   PubMed Web of Science ®Google Scholar
• Karatas H, Aktas Y, Gursoy-Ozdemir Y, et al. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. The J Neurosci. 2009;29:13761–13769.
   PubMed Web of Science ®Google Scholar
• Yemisci M, Caban S, Gursoy-Ozdemir Y, et al. Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection. J Cereb Blood Flow Metab. 2015;35:469–475.
   PubMed Web of Science ®Google Scholar
• Sahin A, Yoyen-Ermis D, Caban-Toktas S, et al. Evaluation of brain-targeted chitosan nanoparticles through blood-brain barrier cerebral microvessel endothelial cells. J Microencapsul. 2017;34:659–666.
   PubMed Web of Science ®Google Scholar
• Gaudin A, Yemisci M, Eroglu H, et al. Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury. Nature Nanotech. 2014;9:1054–1062.
   PubMed Web of Science ®Google Scholar
• Chung NS, Wasan KM. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv drug Deliv Rev. 2004;56:1315–1334.
   PubMed Web of Science ®Google Scholar
• Lajoie JM, Shusta EV. Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu Rev Pharmacol Toxicol. 2015;55:613–631.
   PubMed Web of Science ®Google Scholar
• Pan W, Kastin AJ, Zankel TC, et al. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J Cell Sci. 2004;117:5071–5078.
   PubMed Web of Science ®Google Scholar
• Andrieux K, Couvreur P. Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood-brain barrier. Wires Nanomed Nanobiotechnol. 2009;1:463–474.
   PubMed Web of Science ®Google Scholar
• Zensi A, Begley D, Pontikis C, et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release. 2009;137:78–86.
   PubMed Web of Science ®Google Scholar
• Wagner S, Zensi A, Wien SL, et al. Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model. PloS One. 2012;7:e32568.
   PubMed Web of Science ®Google Scholar
• Demeule M, Regina A, Che C, et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther. 2008;324:1064–1072.
   PubMed Web of Science ®Google Scholar
• Demeule M, Currie JC, Bertrand Y, et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem. 2008;106:1534–1544.
   PubMed Web of Science ®Google Scholar
• Drappatz J, Brenner A, Wong ET, et al. Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res. 2013;19:1567.
   PubMed Web of Science ®Google Scholar
• Ke W, Shao K, Huang R, et al. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials. 2009;30:6976–6985.
   PubMed Web of Science ®Google Scholar
• Kim JS, Shin DH, Kim JS. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells. J Control Release. 2018;269:245–257.
   PubMed Web of Science ®Google Scholar
• Gaillard PJ, Appeldoorn CC, Rip J, et al. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J Control Release. 2012;164:364–369.
   PubMed Web of Science ®Google Scholar
• Lee DH, Rotger C, Appeldoorn CC, et al. Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014;274:96–101.
   PubMed Web of Science ®Google Scholar
• Birngruber T, Raml R, Gladdines W, et al. Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx, Doxil-a cerebral open flow microperfusion pilot study. J Pharm Sci. 2014;103:1945–1948.
   PubMed Web of Science ®Google Scholar
• Rotman M, Welling MM, Bunschoten A, et al. Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease. J Control Release. 2015;203:40–50.
   PubMed Web of Science ®Google Scholar
• Lindqvist A, Rip J, van Kregten J, et al. In vivo functional evaluation of increased brain delivery of the opioid peptide DAMGO by glutathione-PEGylated liposomes. Pharm Res. 2016;33:177–185.
   PubMed Web of Science ®Google Scholar
• Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 2007; 448:39–43.
   PubMed Web of Science ®Google Scholar
• Alvarez-Erviti L, Seow Y, Yin H, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29:341–345.
   PubMed Web of Science ®Google Scholar
• Liu Y, Guo Y, An S, et al. Targeting caspase-3 as dual therapeutic benefits by RNAi facilitating brain-targeted nanoparticles in a rat model of Parkinson's disease. PloS One. 2013;8:e62905.
   PubMed Web of Science ®Google Scholar
• Hwang DW, Son S, Jang J, et al. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 2011;32:4968–4975.
   PubMed Web of Science ®Google Scholar
• Kim JY, Choi WI, Kim YH, et al. Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier. Biomaterials 2013;34:1170–1178.
   PubMed Web of Science ®Google Scholar
• Chen W, Zhan C, Gu B, et al. Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles. J Drug Target. 2011;19:228–234.
   PubMed Web of Science ®Google Scholar
• Liu Y, Huang R, Han L, et al. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 2009;30:4195–4202.
   PubMed Web of Science ®Google Scholar
• Gao Y, Wang ZY, Zhang J, et al. RVG-peptide-linked trimethylated chitosan for delivery of siRNA to the brain. Biomacromolecules. 2014;15:1010–1018.
   PubMed Web of Science ®Google Scholar
• Lee C, Hwang HS, Lee S, et al. Rabies virus-inspired silica-coated gold nanorods as a photothermal therapeutic platform for treating brain tumors. Adv Mater. 2017;29:1605563.
   Web of Science ®Google Scholar
• Conceicao M, Mendonca L, Nobrega C, et al. Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype. Biomaterials. 2016;82:124–137.
   PubMed Web of Science ®Google Scholar
• Cook RL, Householder KT, Chung EP, et al. A critical evaluation of drug delivery from ligand modified nanoparticles: confounding small molecule distribution and efficacy in the central nervous system. J Control Release. 2015;220:89–97.
   PubMed Web of Science ®Google Scholar
• You L, Wang J, Liu T, et al. Targeted brain delivery of rabies virus glycoprotein 29-modified deferoxamine-loaded nanoparticles reverses functional deficits in parkinsonian mice. ACS Nano. 2018;12:4123–4139.
   PubMed Web of Science ®Google Scholar
• Qu M, Lin Q, He S, et al. A brain targeting functionalized liposomes of the dopamine derivative N-3,4-bis(pivaloyloxy)-dopamine for treatment of Parkinson's disease. J Control Release. 2018;277:173–182.
   PubMed Web of Science ®Google Scholar
• Fu A, Wang Y, Zhan L, et al. Targeted delivery of proteins into the central nervous system mediated by rabies virus glycoprotein-derived peptide. Pharm Res. 2012;29:1562–1569.
   PubMed Web of Science ®Google Scholar
• Fu A, Zhao Z, Gao F, et al. Cellular uptake mechanism and therapeutic utility of a novel peptide in targeted-delivery of proteins into neuronal cells. Pharm Res. 2013;30:2108–2117.
   PubMed Web of Science ®Google Scholar
• Benn SC, Ay I, Bastia E, et al. Tetanus toxin fragment C fusion facilitates protein delivery to CNS neurons from cerebrospinal fluid in mice. J Neurochem. 2005;95:1118–1131.
   PubMed Web of Science ®Google Scholar
• Larsen KE, Benn SC, Ay I, et al. A glial cell line-derived neurotrophic factor (GDNF):tetanus toxin fragment C protein conjugate improves delivery of GDNF to spinal cord motor neurons in mice. Brain Res. 2006;1120:1–12.
   PubMed Web of Science ®Google Scholar
• Li J, Chian RJ, Ay I, et al. Insect GDNF:TTC fusion protein improves delivery of GDNF to mouse CNS. Biochem Biophys Res Commun. 2009;390:947–951.
   PubMed Web of Science ®Google Scholar
• Chian RJ, Li J, Ay I, et al. IGF-1:tetanus toxin fragment C fusion protein improves delivery of IGF-1 to spinal cord but fails to prolong survival of ALS mice. Brain Res. 2009;1287:1–19.
   PubMed Web of Science ®Google Scholar
• Kohli N, Westerveld DR, Ayache AC, et al. Oral delivery of bioencapsulated proteins across blood-brain and blood-retinal barriers. Mol Ther. 2014;22:535–546.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu Y, Yang N, et al. Nasal administration of cholera toxin B subunit-nerve growth factor improves the space learning and memory abilities in beta-amyloid protein(25-35)-induced amnesic mice. Neuroscience. 2008;155:234–240.
   PubMed Web of Science ®Google Scholar
• Menon D, Karyekar CS, Fasano A, et al. Enhancement of brain distribution of anticancer agents using DeltaG, the 12 kDa active fragment of ZOT. Int J Pharm. 2005;306:122–131.
   PubMedGoogle Scholar
• Gaillard PJ, Visser CC, de Boer AG. Targeted delivery across the blood-brain barrier. Expert Opin Drug Deliv. 2005;2:299–309.
   PubMed Web of Science ®Google Scholar
• Tosi G, Vilella A, Veratti P, et al. Exploiting bacterial pathways for BBB crossing with PLGA nanoparticles modified with a mutated form of diphtheria toxin (CRM197): in vivo experiments. Mol Pharmaceutics. 2015;12:3672–3684.
   PubMed Web of Science ®Google Scholar
• Hobel S, Appeldoorn CC, Gaillard PJ, et al. Targeted CRM197-PEG-PEI/siRNA complexes for therapeutic RNAi in glioblastoma. Pharmaceuticals. 2011;4:1591–1606.
   Google Scholar
• Zhan C, Yan Z, Xie C, et al. Loop 2 of Ophiophagus hannah toxin b binds with neuronal nicotinic acetylcholine receptors and enhances intracranial drug delivery. Mol Pharmaceutics. 2010;7:1940–1947.
   PubMed Web of Science ®Google Scholar
• Wei X, Zhan C, Shen Q, et al. A D-peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery. Angew Chem Int Ed. 2015;54:3023–3027.
   PubMed Web of Science ®Google Scholar
• Zhan C, Li B, Hu L, et al. Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine receptor ligand. Angew Chem Int Ed. 2011;50:5482–5485.
   PubMed Web of Science ®Google Scholar
• Chai Z, Hu X, Wei X, et al. A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery. J Control Release. 2017;264:102–111.
   PubMed Web of Science ®Google Scholar
• Mahmud H, Kasai T, Khayrani AC, et al. Targeting glioblastoma cells expressing CD44 with liposomes encapsulating Doxorubicin and displaying chlorotoxin-IgG Fc fusion protein. Int J Mol Sci. 2018;19:659.
   Web of Science ®Google Scholar
• Han L, Cai Q, Tian D, et al. Targeted drug delivery to ischemic stroke via chlorotoxin-anchored, lexiscan-loaded nanoparticles. Nanomedicine. 2016;12:1833–1842.
   PubMed Web of Science ®Google Scholar
• Costa PM, Cardoso AL, Custodia C, et al. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: a new multimodal gene therapy approach for glioblastoma. J Control Release. 2015;207:31–39.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Zhu J, Zhao L, et al. 131)I-labeled multifunctional dendrimers modified with BmK CT for targeted SPECT imaging and radiotherapy of gliomas. Nanomedicine. 2016;11:1253–1266.
   PubMed Web of Science ®Google Scholar
• Wu J, Jiang H, Bi Q, et al. Apamin-mediated actively targeted drug delivery for treatment of spinal cord injury: more than just a concept. Mol Pharmaceutics. 2014;11:3210–3222.
   PubMed Web of Science ®Google Scholar
• Oller-Salvia B, Sanchez-Navarro M, Ciudad S, et al. MiniAp-4: A venom-inspired peptidomimetic for brain delivery. Angew Chem Int Ed. 2016;55:572–575.
   PubMed Web of Science ®Google Scholar
• McCall RL, Cacaccio J, Wrabel E, et al. Pathogen-inspired drug delivery to the central nervous system. Tissue Barriers. 2014;2:e944449.
   PubMedGoogle Scholar
• Soddu E, Rassu G, Giunchedi P, et al. From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery. Eur J Pharm Sci. 2015;74:63–76.
   PubMed Web of Science ®Google Scholar
• Salinas S, Schiavo G, Kremer EJ. A hitchhiker's guide to the nervous system: the complex journey of viruses and toxins. Nat Rev Micro. 2010;8:645–655.
   PubMed Web of Science ®Google Scholar
• Lentz TL. Rabies virus binding to an acetylcholine receptor alpha-subunit peptide. J Mol Recognit. 1990;3:82–88.
   PubMedGoogle Scholar
• Leonard S, Bertrand D. Neuronal nicotinic receptors: from structure to function. Nicotine Tob Res. 2001;3:203–223.
   PubMedGoogle Scholar
• Oswald M, Geissler S, Goepferich A. Targeting the central nervous system (CNS): A review of rabies virus-targeting strategies. Mol Pharmaceutics. 2017;14:2177–2196.
   PubMed Web of Science ®Google Scholar
• Ojeda PG, Wang CK, Craik DJ. Chlorotoxin: structure, activity, and potential uses in cancer therapy. Biopolymers. 2016;106:25–36.
   PubMed Web of Science ®Google Scholar
• Butte PV, Mamelak A, Parrish-Novak J, et al. Near-infrared imaging of brain tumors using the tumor paint BLZ-100 to achieve near-complete resection of brain tumors. Neurosurg Focus. 2014;36:E1.
   PubMed Web of Science ®Google Scholar
• Kovar JL, Curtis E, Othman SF, et al. Characterization of IRDye 800CW chlorotoxin as a targeting agent for brain tumors. Anal Biochem. 2013;440:212–219.
   PubMed Web of Science ®Google Scholar
• Jacoby DB, Dyskin E, Yalcin M, et al. Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide. Anticancer Res. 2010;30:39–46.
   PubMed Web of Science ®Google Scholar
• Mamelak AN, Rosenfeld S, Bucholz R, et al. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. JCO. 2006;24:3644–3650.
   PubMed Web of Science ®Google Scholar
• Hockaday DC, Shen S, Fiveash J, et al. Imaging glioma extent with 131I-TM-601. J Nucl Med. 2005;46:580–586.
   PubMed Web of Science ®Google Scholar
• Mamelak AN, Jacoby DB. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv. 2007;4:175–186.
   PubMed Web of Science ®Google Scholar
• Tamborini M, Locatelli E, Rasile M, et al. A Combined approach employing chlorotoxin-nanovectors and low dose radiation to reach infiltrating tumor niches in glioblastoma. ACS Nano. 2016;10:2509–2520.
   PubMed Web of Science ®Google Scholar
• Han L, Kong DK, Zheng MQ, et al. Increased nanoparticle delivery to brain tumors by autocatalytic priming for improved treatment and imaging. ACS Nano. 2016;10:4209–4218.
   PubMed Web of Science ®Google Scholar
• Bazan J, Całkosiński I, Gamian A. Phage display–a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications. Hum Vaccin Immunother. 2012;8:1817–1828.
   PubMed Web of Science ®Google Scholar
• Muruganandam A. , Tanha J., Narang S., et al. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. 2002;16:240–242.
   PubMed Web of Science ®Google Scholar
• Haqqani AS, Delaney CE, Tremblay TL, et al. Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells. Fluids Barriers CNS. 2013;10:4.
   PubMedGoogle Scholar
• Webster CI, Caram-Salas N, Haqqani AS, et al. Brain penetration, target engagement, and disposition of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1. FASEB J. 2016;30:1927–1940.
   PubMed Web of Science ®Google Scholar
• Haqqani AS, Delaney CE, Brunette E, et al. Endosomal trafficking regulates receptor-mediated transcytosis of antibodies across the blood brain barrier. J Cereb Blood Flow Metab. 2018;38:727–740.
   PubMed Web of Science ®Google Scholar
• Li J, Feng L, Fan L, et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials. 2011;32:4943–4950.
   PubMed Web of Science ®Google Scholar
• Qian Y, Zha Y, Feng B, et al. PEGylated poly(2-(dimethylamino) ethyl methacrylate)/DNA polyplex micelles decorated with phage-displayed TGN peptide for brain-targeted gene delivery. Biomaterials. 2013;34:2117–2129.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wan X, Zheng X, et al. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. Biomaterials. 2014;35:456–465.
   PubMed Web of Science ®Google Scholar
• Yu X, Gou X, Wu P, et al. Activatable protein nanoparticles for targeted delivery of therapeutic peptides. Adv Mater. 2018;30:1705383.
   Web of Science ®Google Scholar
• Schwarze SR, Ho A, Vocero-Akbani A, et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285:1569–1572.
   PubMed Web of Science ®Google Scholar
• Uusna J, Langel K, Langel U. Toxicity, immunogenicity, uptake, and kinetics methods for CPPs. Methods Mol Biol. 2015;1324:133–148.
   PubMedGoogle Scholar
• Lim S, Kim WJ, Kim YH, et al. dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis. Nat Commun 2015;6:8244.
   PubMed Web of Science ®Google Scholar
• Li Y, Zheng X, Gong M, et al. Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma. Oncotarget. 2016;7:79401–79407.
   PubMedGoogle Scholar
• Zhu Y, Jiang Y, Meng F, et al. Highly efficacious and specific anti-glioma chemotherapy by tandem nanomicelles co-functionalized with brain tumor-targeting and cell-penetrating peptides. J Control Release. 2018;278:1–8.
   PubMed Web of Science ®Google Scholar
• Li M, Shi K, Tang X. et al. pH-sensitive folic acid and dNP2 peptide dual-modified liposome for enhanced targeted chemotherapy of glioma. Eur J Pharm Sci. 2018;124:240–248.
   PubMed Web of Science ®Google Scholar
• Li M, Shi K, Tang X, et al. Synergistic tumor microenvironment targeting and blood-brain barrier penetration via a pH-responsive dual-ligand strategy for enhanced breast cancer and brain metastasis therapy. Nanomedicine. 2018;14:1833–1843.
   PubMed Web of Science ®Google Scholar